感染症診断市場は、2023年の214億ドルから2028年には315億ドルに成長し、予測期間中に8.0%のCAGRで成長すると予想されます。この市場で事業を展開している主要なプレーヤーは、Abbott(米国)、Thermo Fisher Scientific Inc.(米国)、F. Hoffmann-La Roche Ltd.(スイス)、bioMérieux(フランス)、Siemens Healthineers AG(ドイツ)、Danaher(米国)、Hologic, Inc.(米国)、Becton, Dickinson and Company(米国)、Revvity(米国)、QIAGEN(オランダ)、Seegene Inc.(韓国)、Grifols, S.A.(スペイン)、DiaSorin S.p.A.(イタリア)、Bio-Rad Laboratories, Inc.(米国)、シスメックス株式会社(日本)、 QuidelOrtho Corporation(米国)、Meridian Bioscience(米国)、Genetic Signatures Ltd.(オーストラリア)、OraSure Technologies(米国)、Trinity Biotech(アイルランド)、Chembio Diagnostics, Inc.(米国)、Co-Diagnostics, Inc.(米国)、ELITech Group(フランス)、Epitope Diagnostics, Inc.(米国)、Trivitron Healthcare(インド)、Meril Life Sciences Pvt. Ltd.(インド)、InBios International, Inc.(米国)、Vela Diagnostics(シンガポール)、Uniogen Oy(フィンランド)。
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 33)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 STUDY SCOPE
1.4.1 MARKETS COVERED
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 39)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.2.2.1 Key data from primary sources
2.2.3 KEY INDUSTRY INSIGHTS
2.2.3.1 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.2 COMPANY REVENUE ESTIMATION APPROACH
FIGURE 5 COMPANY REVENUE ESTIMATION APPROACH: INFECTIOUS DISEASE DIAGNOSTICS MARKET
2.3.3 PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
2.3.4 GROWTH FORECAST
2.3.5 CAGR PROJECTIONS
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.6 TOP-DOWN APPROACH
FIGURE 7 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ASSESSMENT
2.6 STUDY ASSUMPTIONS
2.6.1 GROWTH RATE ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: MARKET
2.8 IMPACT OF RECESSION ON MARKET
3 EXECUTIVE SUMMARY (Page No. - 53)
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 15 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 60)
4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
FIGURE 16 GROWING PREVALENCE OF INFECTIOUS DISEASE AND INCREASING INVESTMENT IN R&D TO DRIVE MARKET
4.2 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 17 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 MARKET, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION)
FIGURE 18 LABORATORY TESTING TO DOMINATE MARKET DURING STUDY PERIOD
4.4 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 19 BLOOD, SERUM, AND PLASMA TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
4.5 MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 20 IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD
4.6 MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 21 HEPATITIS TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
4.7 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 22 DIAGNOSTIC LABORATORIES TO DOMINATE MARKET DURING STUDY PERIOD
4.8 REGIONAL GROWTH OPPORTUNITIES
FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 65)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 24 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of infectious diseases
5.2.1.2 Rising focus on R&D and funding for infectious disease diagnostic products
5.2.1.3 Growing awareness for early disease diagnosis in emerging economies
5.2.1.4 Adoption of new and advanced technologies for infectious disease diagnosis
5.2.1.5 Shift in focus from centralized laboratories to decentralized PoC testing centers
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Increased growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape
5.2.4.2 Operational barriers and shortage of skilled laboratory technicians
5.3 PRICING ANALYSIS
TABLE 2 INDICATIVE PRICING FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
TABLE 3 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION
5.4 PATENT ANALYSIS
FIGURE 25 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013-DECEMBER 2022)
TABLE 4 LIST OF MAJOR PATENTS, JANUARY 2021-DECEMBER 2022
5.5 VALUE CHAIN ANALYSIS
FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 27 SUPPLY CHAIN ANALYSIS: MARKET
5.7 ECOSYSTEM MARKET MAP
FIGURE 28 ECOSYSTEM MARKET MAP: MARKET
TABLE 5 ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.2 NORTH AMERICA
5.9.2.1 US
5.9.2.2 Canada
5.9.3 EUROPE
TABLE 11 EUROPE: CLASSIFICATION OF DEVICES
5.9.4 ASIA PACIFIC
5.9.4.1 China
5.9.4.2 Japan
TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.9.4.3 India
5.9.5 LATIN AMERICA
5.9.5.1 Brazil
5.9.5.2 Mexico
5.9.6 MIDDLE EAST
5.9.6.1 Africa
5.10 TRADE ANALYSIS
TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES & EVENTS
TABLE 15 DETAILED LIST OF KEY CONFERENCES & EVENTS IN 2O22-2023
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 29 REVENUE SHIFT IN MARKET
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
5.14.2 BUYING CRITERIA
FIGURE 31 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
TABLE 17 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
5.15 CASE STUDY ANALYSIS
FIGURE 32 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 93)
6.1 INTRODUCTION
TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 19 PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2022
6.2 REAGENTS, KITS, AND CONSUMABLES
6.2.1 RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO DRIVE MARKET
TABLE 20 MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS WITH MINIMUM HUMAN INTERVENTION TO DRIVE MARKET
TABLE 21 KEY INSTRUMENTS AVAILABLE IN MARKET
TABLE 22 MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS AND INCREASING COMPETITIVENESS FOR VALUE-ADDED SERVICES TO DRIVE MARKET
TABLE 23 MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING (Page No. - 100)
7.1 INTRODUCTION
TABLE 24 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY TYPE OF TESTING, 2021-2028 (USD MILLION)
7.1.1 PRIMARY NOTES
FIGURE 33 KEY INDUSTRY INSIGHTS: MARKET, BY TYPE OF TESTING
7.2 LABORATORY TESTING
7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
TABLE 25 MARKET FOR LABORATORY TESTING, BY REGION, 2021-2028 (USD MILLION)
7.3 POC TESTING
7.3.1 FASTER TURNAROUND TIME AND MORE EFFICIENT TREATMENT OPTIONS TO DRIVE MARKET
TABLE 26 MARKET FOR POC TESTING, BY REGION, 2021-2028 (USD MILLION)
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE (Page No. - 105)
8.1 INTRODUCTION
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
8.1.1 PRIMARY NOTES
FIGURE 34 KEY INDUSTRY INSIGHTS: MARKET, BY SAMPLE TYPE
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 HIGHER VERSATILITY, GREATER CLINICAL EFFICACY, AND BETTER REIMBURSEMENT POLICIES TO DRIVE MARKET
TABLE 28 MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021-2028 (USD MILLION)
8.3 URINE
8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO DRIVE MARKET
TABLE 29 MARKET FOR URINE, BY REGION, 2021-2028 (USD MILLION)
8.4 OTHER SAMPLE TYPES
TABLE 30 MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021-2028 (USD MILLION)
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE (Page No. - 110)
9.1 INTRODUCTION
TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY DISEASE TYPE, 2021-2028 (USD MILLION)
9.2 HEPATITIS
TABLE 32 MARKET FOR HEPATITIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 33 MARKET FOR HEPATITIS, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 34 MARKET FOR HEPATITIS, BY METHOD, 2021-2028 (USD MILLION)
TABLE 35 MARKET FOR HEPATITIS, BY TYPE, 2021-2028 (USD MILLION)
9.2.1 HEPATITIS B
9.2.1.1 Increasing global prevalence of hepatitis B to drive segment
TABLE 36 HEPATITIS B MARKET, BY REGION, 2021-2028 (USD MILLION)
9.2.2 HEPATITIS C
9.2.2.1 Rising number of government initiatives for hepatitis C diagnosis to drive segment
TABLE 37 HEPATITIS C MARKET, BY REGION, 2021-2028 (USD MILLION)
9.2.3 OTHER HEPATITIS DISEASES
TABLE 38 OTHER HEPATITIS DISEASES MARKET, BY REGION, 2021-2028 (USD MILLION)
9.3 HIV
9.3.1 GROWING PREVALENCE OF AIDS AND INCREASING AVAILABILITY OF HIV POC TESTING TO DRIVE MARKET
TABLE 39 MARKET FOR HIV, BY REGION, 2021-2028 (USD MILLION)
TABLE 40 MARKET FOR HIV, BY REGION, 2021-2028 (MILLION TESTS)
9.4 HOSPITAL-ACQUIRED INFECTIONS
9.4.1 RISING BURDEN OF INFECTIONS AND INCREASING ADOPTION OF ADVANCED DIAGNOSTIC TESTS TO DRIVE MARKET
TABLE 41 MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021-2028 (USD MILLION)
TABLE 42 MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021-2028 (MILLION TESTS)
9.5 MOSQUITO-BORNE DISEASES
9.5.1 RISING INCIDENCE OF DENGUE AND MALARIA AND INCREASING NUMBER OF AWARENESS PROGRAMS TO DRIVE MARKET
TABLE 43 MAJOR PRODUCTS FOR DENGUE TESTING AVAILABLE IN MARKET
TABLE 44 MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2021-2028 (USD MILLION)
9.6 HPV
9.6.1 TECHNOLOGICAL ADVANCEMENTS FOR PREVENTING HPV INFECTIONS TO DRIVE MARKET
TABLE 45 MARKET FOR HPV, BY REGION, 2021-2028 (USD MILLION)
TABLE 46 MARKET FOR HPV, BY REGION, 2021-2028 (MILLION TESTS)
9.7 CHLAMYDIA TRACHOMATIS
9.7.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET
TABLE 47 MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 48 MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021-2028 (MILLION TESTS)
9.8 NEISSERIA GONORRHEA
9.8.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET
TABLE 49 MARKET FOR NEISSERIA GONORRHEA, BY REGION, 2021-2028 (USD MILLION)
9.9 TUBERCULOSIS
9.9.1 INCREASING BURDEN OF TUBERCULOSIS IN UNDERDEVELOPED NATIONS TO DRIVE MARKET
TABLE 50 MARKET FOR TUBERCULOSIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 51 MARKET FOR TUBERCULOSIS, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 52 MARKET FOR TUBERCULOSIS, BY METHOD, 2021-2028 (USD MILLION)
9.10 INFLUENZA
9.10.1 RISING FOCUS ON FASTER DIAGNOSIS AND CONTROL TO DRIVE MARKET
TABLE 53 MARKET FOR INFLUENZA, BY REGION, 2021-2028 (USD MILLION)
TABLE 54 MARKET FOR INFLUENZA, BY REGION, 2021-2028 (MILLION TESTS)
TABLE 55 MARKET FOR INFLUENZA, BY METHOD, 2021-2028 (USD MILLION)
9.11 SYPHILIS
9.11.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES FOR IMPROVED SCREENING TO DRIVE MARKET
TABLE 56 MARKET FOR SYPHILIS, BY REGION, 2021-2028 (USD MILLION)
9.12 OTHER INFECTIOUS DISEASES
TABLE 57 MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
9.13 COVID-19
9.13.1 DECLINING CASES OF COVID-19 TO LIMIT MARKET
TABLE 58 MARKET FOR COVID-19, BY REGION, 2021-2028 (USD MILLION)
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 131)
10.1 INTRODUCTION
10.2 PRIMARY NOTES
FIGURE 35 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY TECHNOLOGY
TABLE 59 MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
10.3 IMMUNODIAGNOSTICS
10.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET
TABLE 60 MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
10.4 CLINICAL MICROBIOLOGY
10.4.1 QUICKER TURNAROUND TIME FOR RESULTS WITH HIGHER SENSITIVITY AND RELIABILITY TO DRIVE MARKET
TABLE 61 MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2021-2028 (USD MILLION)
10.5 POLYMERASE CHAIN REACTION
10.5.1 EASE OF USE, COST-EFFECTIVENESS, AND HIGH SPECIFICITY TO DRIVE MARKET
TABLE 62 MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021-2028 (USD MILLION)
10.6 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
10.6.1 LOWER COST AND BETTER SUITABILITY FOR POINT-OF-CARE TESTING TO DRIVE MARKET
TABLE 63 MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021-2028 (USD MILLION)
10.7 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
10.7.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND INCREASED FOCUS ON MOLECULAR TARGETED DRUGS TO DRIVE MARKET
TABLE 64 MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
10.8 DNA MICROARRAY
10.8.1 HIGH INSTRUMENT COSTS AND NEED FOR EXPERT TECHNICIANS TO LIMIT MARKET
TABLE 65 MARKET FOR DNA MICROARRAY, BY REGION, 2021-2028 (USD MILLION)
10.9 OTHER TECHNOLOGIES
TABLE 66 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER (Page No. - 141)
11.1 INTRODUCTION
TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
11.2 DIAGNOSTIC LABORATORIES
11.2.1 DEVELOPMENT OF LOW-COST AND HIGHLY SPECIALIZED SCREENING TESTS TO DRIVE MARKET
TABLE 68 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
11.3 HOSPITALS & CLINICS
11.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND BETTER REIMBURSEMENT FACILITIES TO DRIVE MARKET
TABLE 69 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021-2028 (USD MILLION)
11.4 ACADEMIC RESEARCH INSTITUTES
11.4.1 INCREASING FOCUS ON R&D FOR DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET
TABLE 70 MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
11.5 OTHER END USERS
TABLE 71 MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION (Page No. - 147)
12.1 INTRODUCTION
TABLE 72 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 36 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
TABLE 73 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 74 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 75 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 76 NORTH AMERICA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.1 NORTH AMERICA: RECESSION IMPACT
12.2.2 US
12.2.2.1 Increasing prevalence of infectious diseases to drive market
TABLE 78 US: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 79 US: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 80 US: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 81 US: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.3 CANADA
12.2.3.1 Focus on affordable tests and use of personalized medicine to drive market
TABLE 82 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 83 CANADA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 84 CANADA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 85 CANADA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3 EUROPE
TABLE 86 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 87 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 88 EUROPE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 89 EUROPE: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 90 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.1 EUROPE: RECESSION IMPACT
12.3.2 GERMANY
12.3.2.1 Increasing healthcare expenditure and rising per capita disposable income to drive market
TABLE 91 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 92 GERMANY: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 93 GERMANY: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 94 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.3 UK
12.3.3.1 Growing number of accredited diagnostic and hospital laboratories to drive market
TABLE 95 UK: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 96 UK: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 97 UK: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 98 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.4 FRANCE
12.3.4.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market
TABLE 99 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 100 FRANCE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 101 FRANCE: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 102 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.5 ITALY
12.3.5.1 Increased adoption of advanced diagnostic technologies and growing government healthcare investment to drive market
TABLE 103 ITALY: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 104 ITALY: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 105 ITALY: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 106 ITALY: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.6 SPAIN
12.3.6.1 Rising geriatric population and improving healthcare infrastructure to drive market
TABLE 107 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 108 SPAIN: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 109 SPAIN: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 110 SPAIN: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.7 REST OF EUROPE
TABLE 111 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%)
TABLE 112 REST OF EUROPE: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 113 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 114 REST OF EUROPE: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 115 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4 ASIA PACIFIC
FIGURE 37 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
TABLE 116 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 118 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 119 ASIA PACIFIC: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 120 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.1 ASIA PACIFIC: RECESSION IMPACT
12.4.2 CHINA
12.4.2.1 Increased public access to modern healthcare and favorable government policies to drive market
TABLE 121 CHINA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 122 CHINA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 123 CHINA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 124 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.3 JAPAN
12.4.3.1 Presence of well-developed healthcare system and universal reimbursement policies to drive market
TABLE 125 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 126 JAPAN: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 127 JAPAN: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 128 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.4 INDIA
12.4.4.1 Increasing private and public investments in healthcare system to drive market
TABLE 129 INDIA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 130 INDIA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 131 INDIA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 132 INDIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.5 REST OF ASIA PACIFIC
TABLE 133 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 134 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 135 REST OF ASIA PACIFIC: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 136 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5 LATIN AMERICA
12.5.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET
TABLE 137 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 138 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 139 LATIN AMERICA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 140 LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.2 LATIN AMERICA: RECESSION IMPACT
12.6 MIDDLE EAST & AFRICA
TABLE 141 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 142 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 143 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 144 MIDDLE EAST & AFRICA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 145 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
12.6.2 GCC COUNTRIES
12.6.2.1 Rising focus on advanced health infrastructure to drive market
TABLE 146 GCC COUNTRIES: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 147 GCC COUNTRIES: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 148 GCC COUNTRIES: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 149 GCC COUNTRIES: MARKET, BY END USER, 2021-2028 (USD MILLION)
12.6.3 REST OF MIDDLE EAST & AFRICA
TABLE 150 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 151 REST OF MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 152 REST OF MIDDLE EAST & AFRICA: MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
TABLE 153 REST OF MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
13 COMPETITIVE LANDSCAPE (Page No. - 197)
13.1 OVERVIEW
13.2 KEY STRATEGIES/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 154 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
13.3 REVENUE SHARE ANALYSIS
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS
13.4 MARKET SHARE ANALYSIS
FIGURE 39 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY SHARE, BY KEY PLAYER (2022)
TABLE 155 DEGREE OF COMPETITION: INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY
13.5 COMPANY EVALUATION MATRIX
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
FIGURE 40 COMPANY EVALUATION MATRIX, 2022
13.5.5 COMPANY FOOTPRINT
FIGURE 41 PRODUCT AND REGIONAL FOOTPRINT OF KEY PLAYERS
TABLE 156 COMPANY FOOTPRINT
TABLE 157 PRODUCT & SERVICE FOOTPRINT
TABLE 158 REGIONAL FOOTPRINT
13.6 START-UP/SME EVALUATION MATRIX
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
FIGURE 42 START-UP/SME EVALUATION MATRIX, 2022
13.6.5 COMPETITIVE BENCHMARKING
TABLE 159 DETAILED LIST OF KEY START-UPS/SMES
13.7 COMPETITIVE SCENARIOS AND TRENDS
13.7.1 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 160 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS, 2020-2023
13.7.2 KEY DEALS
TABLE 161 KEY DEALS, 2020-2023
14 COMPANY PROFILES (Page No. - 210)
14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 162 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
14.1.2 ABBOTT
TABLE 163 ABBOTT: COMPANY OVERVIEW
FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2022)
14.1.3 BIOMÉRIEUX
TABLE 164 BIOMÉRIEUX: COMPANY OVERVIEW
FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
14.1.4 SIEMENS HEALTHINEERS AG
TABLE 165 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
14.1.5 DANAHER
TABLE 166 DANAHER: COMPANY OVERVIEW
FIGURE 47 DANAHER: COMPANY SNAPSHOT (2022)
14.1.6 THERMO FISHER SCIENTIFIC INC.
TABLE 167 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 48 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
14.1.7 HOLOGIC, INC.
TABLE 168 HOLOGIC, INC.: COMPANY OVERVIEW
FIGURE 49 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
14.1.8 BECTON, DICKINSON AND COMPANY
TABLE 169 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 50 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
14.1.9 REVVITY
TABLE 170 REVVITY: COMPANY OVERVIEW
FIGURE 51 REVVITY: COMPANY SNAPSHOT (2022)
14.1.10 QIAGEN
TABLE 171 QIAGEN: COMPANY OVERVIEW
FIGURE 52 QIAGEN: COMPANY SNAPSHOT (2022)
14.1.11 SEEGENE INC.
TABLE 172 SEEGENE INC.: COMPANY OVERVIEW
FIGURE 53 SEEGENE INC.: COMPANY SNAPSHOT (2022)
14.2 OTHER PLAYERS
14.2.1 QUIDELORTHO CORPORATION
14.2.2 GRIFOLS, S.A.
14.2.3 DIASORIN S.P.A.
14.2.4 BIO-RAD LABORATORIES, INC.
14.2.5 SYSMEX CORPORATION
14.2.6 ORASURE TECHNOLOGIES
14.2.7 CO-DIAGNOSTICS, INC.
14.2.8 MERIDIAN BIOSCIENCE
14.2.9 CHEMBIO DIAGNOSTICS, INC.
14.2.10 TRINITY BIOTECH
14.2.11 GENETIC SIGNATURES LTD.
14.2.12 EPITOPE DIAGNOSTICS, INC.
14.2.13 TRIVITRON HEALTHCARE
14.2.14 ELITECH GROUP
14.2.15 MERIL LIFE SCIENCES PVT. LTD.
14.2.16 INBIOS INTERNATIONAL, INC.
14.2.17 UNIOGEN OY
14.2.18 VELA DIAGNOSTICS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX (Page No. - 301)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
